- Home
- COEP vs GTBP Comparison
COEP vs GTBP Comparison
Compare COEP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- GTBP
- Stock Information
- Founded
- COEP 2017
- GTBP 1965
- Country
- COEP United States
- GTBP United States
- Employees
- COEP N/A
- GTBP N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- GTBP Health Care
- Exchange
- COEP Nasdaq
- GTBP Nasdaq
- Market Cap
- COEP 8.1M
- GTBP 6.6M
- IPO Year
- COEP N/A
- GTBP N/A
- Fundamental
- Price
- COEP $0.21
- GTBP $2.91
- Analyst Decision
- COEP
- GTBP
- Analyst Count
- COEP 0
- GTBP 0
- Target Price
- COEP N/A
- GTBP N/A
- AVG Volume (30 Days)
- COEP 282.8K
- GTBP 28.8K
- Earning Date
- COEP 11-13-2024
- GTBP 11-19-2024
- Dividend Yield
- COEP N/A
- GTBP N/A
- EPS Growth
- COEP N/A
- GTBP N/A
- EPS
- COEP N/A
- GTBP N/A
- Revenue
- COEP N/A
- GTBP N/A
- Revenue This Year
- COEP N/A
- GTBP N/A
- Revenue Next Year
- COEP N/A
- GTBP N/A
- P/E Ratio
- COEP N/A
- GTBP N/A
- Revenue Growth
- COEP N/A
- GTBP N/A
- 52 Week Low
- COEP $0.15
- GTBP $1.92
- 52 Week High
- COEP $1.33
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- COEP 50.31
- GTBP 55.53
- Support Level
- COEP $0.19
- GTBP $2.94
- Resistance Level
- COEP $0.22
- GTBP $3.54
- Average True Range (ATR)
- COEP 0.02
- GTBP 0.27
- MACD
- COEP -0.00
- GTBP -0.02
- Stochastic Oscillator
- COEP 46.15
- GTBP 23.05
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.